Leif Bertilsson
#111,895
Most Influential Person Now
Leif Bertilsson's AcademicInfluence.com Rankings
Leif Bertilssonmedical Degrees
Medical
#1526
World Rank
#1874
Historical Rank
Pharmacology
#129
World Rank
#163
Historical Rank
Download Badge
Medical Chemistry
Leif Bertilsson's Degrees
- Masters Pharmacy Uppsala University
- Bachelors Pharmacy Uppsala University
Why Is Leif Bertilsson Influential?
(Suggest an Edit or Addition)Leif Bertilsson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (2006) (724)
- Monoamine metabolites in CSF and suicidal behavior. (1981) (679)
- Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. (1993) (661)
- "Serotonin depression"--a biochemical subgroup within the affective disorders? (2003) (651)
- Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. (2002) (507)
- Geographical/Interracial Differences in Polymorphic Drug Oxidation (1995) (462)
- Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. (1994) (459)
- Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin (1992) (420)
- Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. (1996) (391)
- Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. (1995) (338)
- 10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes (1998) (304)
- Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. (1980) (290)
- Homicide, suicide and CSF 5‐HIAA (1985) (282)
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. (1994) (278)
- Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls (1981) (278)
- CSF monoamine metabolites in melancholia (1984) (275)
- Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service (1994) (271)
- Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans (2007) (249)
- Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype (1989) (245)
- CSF 5-HIAA predicts suicide risk after attempted suicide. (1994) (242)
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine (1993) (240)
- Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline (1973) (239)
- Pharmacokinetics of indomethacin (1975) (236)
- Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. (2001) (231)
- Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide (1986) (229)
- Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. (1995) (221)
- E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation (1981) (198)
- Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. (1995) (196)
- A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. (2003) (195)
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. (2003) (192)
- Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. (2012) (190)
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. (1992) (186)
- Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. (2003) (181)
- Clinical Pharmacokinetics of Carbamazepine (1978) (181)
- Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities (1982) (180)
- Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. (1990) (179)
- 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. (2011) (176)
- Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. (1985) (166)
- Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings (1989) (160)
- Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study (2003) (160)
- Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. (1992) (157)
- The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes (2003) (156)
- Polymorphic debrisoquin hydroxylation in 757 Swedish subjects (1988) (156)
- Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. (2008) (154)
- 4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians (2008) (153)
- D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. (1995) (146)
- Relationship between personality and debrisoquine hydroxylation capacity (1993) (143)
- Polymorphic Drug Oxidation (1996) (141)
- Genetically variable metabolism of antidepressants and neuroleptic drugs in man. (1993) (141)
- S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin (1989) (138)
- Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique (1980) (134)
- Aging-induced Changes in Acetylcholine and Serotonin Content of Discrete Brain Nuclei (1977) (133)
- Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β‐Hydroxycholesterol (2008) (129)
- Carbamazepine Metabolism in Man (1985) (128)
- CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. (1996) (127)
- Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. (2000) (127)
- Methylation of mercury compounds by methylcobalamin. (1971) (127)
- Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine (1998) (124)
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. (1980) (120)
- Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity (1996) (119)
- DEBRISOQUINE HYDROXYLATION POLYMORPHISM AND PERSONALITY (1989) (118)
- Cortisol in the CSF of depressed and suicidal patients. (1980) (118)
- Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients (1999) (116)
- Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations (2013) (116)
- Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. (2005) (115)
- 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. (2009) (114)
- Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. (1979) (110)
- Quantitative determination of 5-hydroxyindole-3-acetic acid in cerebrospinal fluid by gas chromatography-mass spectrometry. (1972) (110)
- LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION (1987) (109)
- Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes (2008) (104)
- No sex‐related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects (2000) (104)
- Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. (1995) (103)
- Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. (1987) (101)
- Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. (1992) (101)
- Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test (2001) (100)
- Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. (1994) (100)
- Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects (1997) (99)
- The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. (1983) (99)
- Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype (1998) (97)
- High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. (1999) (97)
- Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. (2003) (96)
- S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. (1996) (96)
- Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. (1996) (96)
- SLOW HYDROXYLATION OF NORTRIPTYLINE AND CONCOMITANT POOR DEBRISOQUINE HYDROXYLATION: CLINICAL IMPLICATIONS (1981) (95)
- Artemisinin induces omeprazole metabolism in human beings (1998) (94)
- The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol (1996) (92)
- Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers (1986) (91)
- Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin (2000) (90)
- Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. (2002) (90)
- Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe (1995) (90)
- Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S‐mephenytoin (1997) (90)
- CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population (2006) (89)
- CSF monoamine metabolites of depressed patients during illness and after recovery (1984) (89)
- Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. (1999) (88)
- Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (2002) (88)
- Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes (1998) (88)
- The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity (2002) (87)
- Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis (2011) (86)
- Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. (2001) (86)
- Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects (2007) (86)
- Suicide attempts and impulse control disorder are related to low cerebrospinalfluid 5‐HIAA in mentally disorderedviolent offenders (2000) (85)
- Mass fragmentographic quantitation of glutamic acid and gamma-aminobutyric acid in cerebellar nuclei and sympathetic ganglia of rats. (1976) (83)
- Interethnic factors affecting drug response (1994) (81)
- Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation (1983) (80)
- Quantitative determination of 4-hydroxy-3-methoxyphenyl glycol and its conjugates in cerebrospinal fluid by mass fragmentography. (1973) (79)
- Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. (1999) (79)
- Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses (1975) (78)
- In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans (1997) (77)
- CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients (2000) (77)
- Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. (2001) (77)
- Fluoxetine treatment of depression (1989) (77)
- Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. (2000) (77)
- Application of principles of steady-state kinetics to the estimation of gamma-aminobutyric acid turnover rate in nuclei of rat brain. (1977) (75)
- CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir (2007) (73)
- Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. (1985) (72)
- Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects (2008) (72)
- Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors (1998) (70)
- Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. (1980) (69)
- Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. (2003) (69)
- Diazepam metabolism in native Chinese poor and extensive hydroxylators of S‐mephenytoin: Interethnic differences in comparison with white subjects (1990) (69)
- Comparison of Endogenous 4β-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin (2013) (68)
- Antidepressants and drug‐metabolizing enzymes — expert group report (1996) (67)
- Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. (1984) (66)
- Single‐dose kinetics and metabolism of carbamazepine‐10,11‐epoxide (1983) (65)
- Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype (1990) (65)
- Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans (1991) (65)
- Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. (1999) (63)
- Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients (2001) (63)
- Interindividual differences in amitriptyline demethylation (1980) (63)
- Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. (2003) (62)
- CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels (2008) (61)
- Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype (1996) (60)
- Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients (2010) (60)
- DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE (1989) (59)
- The Use of Therapeutic Drug Monitoring Data to Document Kinetic Drug Interactions: An Example with Amitriptyline and Nortriptyline (1994) (59)
- Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers (2009) (58)
- The turnover rate of gamma-aminobutyric acid in the nuclei of telencephalon: implications in the pharmacology of antipsychotics and of a minor tranquilizer. (1977) (57)
- CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction (2008) (57)
- Quantitative determination of carbamazepine in plasma by mass fragmentography (1973) (57)
- Active Hydroxymetabolites of Antidepressants (1995) (57)
- Bromocriptine treatment of depressive disorders (1981) (56)
- Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine (2004) (56)
- Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. (2003) (55)
- Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls (1982) (55)
- CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking (2010) (54)
- Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. (1981) (54)
- Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of α2-adrenoceptor blockade (1999) (53)
- Pharmacokinetics: Time‐Dependent Changes— Autoinduction of Carbamazepine Epoxidation (1986) (52)
- Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study (2001) (52)
- Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism (1994) (52)
- Indole-3-Acetic Acid in-Human Cerebrospinal Fluid: Identification and Quantification by Mass Fragmentography (1972) (51)
- Metabolism and elimination of quinine in healthy volunteers (2003) (50)
- Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. (1975) (50)
- MONOAMINE METABOLITES IN CEREBROSPINAL FLUID IN RELATION TO DEPRESSIVE ILLNESS, SUICIDAL BEHAVIOUR AND PERSONALITY (1981) (50)
- Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. (1999) (50)
- Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI) (2008) (49)
- Carbamazepine-10,11-epoxide in epilepsy. A pilot study. (1990) (49)
- Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. (1999) (47)
- Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism (1984) (46)
- Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. (1983) (45)
- Serotonin in Depressive Illness – Studies of CSF 5-HIAA (1979) (45)
- Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism (2004) (45)
- Clinical and biochemical effects during treatment of depression with nortriptyline: The role of 10‐hydroxynortriptyline (1987) (45)
- The roles of cytochrome P450 3A4 and lA2 in the 3‐hydroxylation of quinine in vivo (1999) (45)
- Higher CSF levels of HVA and 5-HIAA in delusional compared to nondelusional depression. (1985) (44)
- MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs (2009) (44)
- Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients (2012) (43)
- Site of lumbar puncture influences levels of monoamine metabolites. (1982) (43)
- Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. (2008) (43)
- γ-Aminobutyric acid in rat superior cervical ganglion (1976) (43)
- Monitoring Tricyclic Antidepressants (1980) (42)
- The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. (1997) (41)
- Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man (2003) (41)
- Effects of antidepressant treatments on platelet tritiated imipramine binding in major depressive disorder. (1987) (41)
- Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: methodological aspects. (1984) (41)
- Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin (2006) (41)
- Voriconazole and fluconazole increase the exposure to oral diazepam (2007) (40)
- Reduction of tryptophan hydroxylase activity and 5-hydroxytryptamine concentration in certain rat brain nuclei after p-chloroamphetamine. (1976) (39)
- Enantioselective Hydroxylation of Nortriptyline in Human Liver Microsomes, Intestinal Homogenate, and Patients Treated with Nortriptyline (1991) (38)
- Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. (1992) (38)
- Pharmacokinetics and biological effects of nortriptyline in man. (2009) (38)
- CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited (2007) (38)
- Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. (2004) (37)
- Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders (2000) (37)
- Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers (2007) (37)
- CSF monoamine metabolites, depression, and suicide. (1984) (36)
- Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines (2006) (36)
- Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects (1986) (36)
- Why are diazepam metabolism and polymorphic S‐mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? (1993) (35)
- Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects (1984) (35)
- A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. (1992) (35)
- Detection of N‐Terminally Extended Substance P but Not of Substance P in Human Cerebrospinal Fluid: Quantitation with HPLC‐Radioimmunoassay (1988) (35)
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine (1980) (35)
- Distribution and elimination kinetics of carbamazepine in man (1975) (34)
- Clinical pharmacology of antidepressant drugs: pharmacogenetics. (1984) (33)
- Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19 (1999) (33)
- Genetic polymorphism of cytochrome P450s and P‐glycoprotein in the Finnish population (2007) (33)
- Interaction of Carbamazepine‐10,11‐Epoxide, an Active Metabolite of Carbamazepine, with Valproate: A Pharmacokinetic Study (1990) (32)
- Stereoselective disposition of racemic E‐10‐hydroxynortriptyline in human beings (1989) (32)
- 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. (1998) (31)
- Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. (1988) (31)
- Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype (2000) (31)
- Pharmacogenetics in clinical pharmacology and toxicology. (1995) (30)
- Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance (2012) (30)
- Xanthine oxidase activity is influenced by environmental factors in Ethiopians (2003) (30)
- Effect of Terbinafine and Voriconazole on the Pharmacokinetics of the Antidepressant Venlafaxine (2008) (30)
- Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions (2005) (29)
- CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. (1985) (29)
- Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation (2012) (29)
- Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression (1974) (29)
- The single nucleotide polymorphism T1128C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population (2002) (29)
- Factors influencing the metabolism of diazepam. (1990) (28)
- Antiepileptic Drugs Increase Plasma Levels of 4β-Hydroxycholesterolin Humans (2001) (27)
- Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. (1999) (25)
- CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. (1998) (25)
- Genetic and Clinical Factors Affecting Plasma Clozapine Concentration. (2015) (24)
- Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. (1999) (24)
- Determination of isomeric acid dopamine metabolites in human cerebrospinal fluid by mass fragmentography. (1973) (24)
- Glucuronidation of amitriptyline in man in vivo. (1989) (24)
- Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo (2006) (23)
- Hydroxylation and subsequent glucuronide conjugation of desmethylimipramine in rat liver microsomes. (1971) (23)
- CYP2D6 polymorphism is not crucial for the disposition of selegiline (1998) (23)
- Alaproclate a novel antidepressant? (1985) (23)
- UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems (2012) (23)
- Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. (2015) (23)
- High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. (2014) (23)
- The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans (2015) (23)
- Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation. (1986) (23)
- Formation of a quaternary N-glucuronide of amitriptyline in human liver microsomes. (1987) (22)
- Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. (2001) (22)
- Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. (1988) (22)
- Monoamine Metabolites Level in CSF is Related to the 5-HTT Gene Polymorphism in Treatment-Resistant Depression (2007) (22)
- Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin. (2014) (22)
- Little anticholinergic effect of E‐10‐hydroxynortriptyline compared with nortriptyline in healthy subjects (1987) (21)
- Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. (2014) (21)
- Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. (1984) (21)
- Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. (1979) (21)
- VALPROMIDE/CARBAMAZEPINE AND RISK OF TERATOGENICITY (1985) (21)
- 5-Hydroxytryptamine depletion in mesencephalic nuclei of rat brain following a single injection of p-chloroamphetamine (1975) (21)
- Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. (1994) (20)
- Glucuronidation of E-10-hydroxynortriptyline in human liver, kidney, and intestine. Organ-specific differences in enantioselectivity. (1989) (20)
- HYDROXYLATION OF DEBRISOQUINE IN PATIENTS WITH LACTICACIDOSIS AFTER PHENFORMIN (1981) (20)
- Voriconazole Increases while Itraconazole Decreases Plasma Meloxicam Concentrations (2008) (19)
- CYP2D6, serotonin, and suicide—a relationship? (2010) (19)
- Nonstereoselective disposition of ethosuximide in humans. (1990) (19)
- Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. (2000) (19)
- Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects (2005) (18)
- Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol (2011) (18)
- N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians (2018) (18)
- Single‐Dose Kinetics of an Enteric‐Coated Formulation of Carbamazepine‐10,11‐epoxide, an Active Metabolite of Carbamazepine (1988) (18)
- Determination of Exogenous Melatonin and Its 6-Hydroxy Metabolite in Human Plasma by Liquid Chromatography–Mass Spectrometry (2001) (18)
- Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy (1976) (18)
- 5-Hydroxyindoleacetic acid in cerebrospinal fluid--methodological and clinical aspects. (1987) (18)
- Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. (2015) (17)
- Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. (2003) (17)
- Glucuronidation of the enantiomers of E-10-hydroxynortriptyline in human and rat liver microsomes. (1987) (17)
- d-Propoxyphene is a Potent Inhibitor of Debrisoquine, but Not S-Mephenytoin 4‐Hydroxylation In Vivo (1990) (17)
- Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. (1993) (17)
- Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. (1988) (16)
- Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine (2010) (16)
- No interaction of diazepam on amitriptyline disposition in depressed patients. (1987) (16)
- Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease (2010) (16)
- Plasma haloperidol levels and clinical response in acute schizophrenia (1984) (16)
- Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes (2012) (16)
- Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. (2013) (16)
- Comparison of N‐Acetyltransferase‐2 Enzyme Genotype‐Phenotype and Xanthine Oxidase Enzyme Activity Between Swedes and Koreans (2012) (16)
- Enantioselective Determination of Mianserin and Its Desmethyl Metabolite in Plasma During Treatment of Depressed Japanese Patients (1995) (15)
- Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans. (1995) (15)
- E- and Z-10-hydroxylation of nortriptyline by human liver microsomes--methods and characterization. (1983) (15)
- Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. (2003) (15)
- Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level (1972) (15)
- CYP2D6, serotonin and suicide. (2010) (15)
- Mechanism of action of benzodiazepines—the GABA hypothesis (1978) (15)
- Lower CYP2C9 activity in Turkish patients with Behçet’s disease compared to healthy subjects: a down-regulation due to inflammation? (2015) (14)
- Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. (1993) (14)
- CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline (2001) (14)
- Urinary excretion of 5‐hydroxyindoleacetic acid – no relationship to the level in cerebrospinal fluid (1982) (14)
- Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. (1990) (14)
- Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man? (2002) (14)
- Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state (1997) (14)
- Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients (2018) (13)
- Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. (1991) (13)
- Disposition of placentally transferred carbamazepine (Tegretol®) in the newborn (1975) (13)
- Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9 (2010) (13)
- Comparison of the effects of lesion in the ‘B9’ cell body group andp-chloroamphetamine on tryptophan hydroxylase and 5-hydroxytryptamine in rat brain nuclei (1975) (13)
- Long‐Term Effect of Rifampicin‐Based Anti‐TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8‐Hydroxy‐Efavirenz in Ethiopian Patients (2016) (12)
- Nortriptyline formation after single oral and intramuscular doses of amitriptyline (1982) (12)
- Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. (1999) (12)
- CARBAMAZEPINE UPDATE (1989) (12)
- Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease (2017) (11)
- Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency (2016) (11)
- Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients (2014) (11)
- Biochemical effects of zimelidine in man (1980) (11)
- The absence of isotopic effect during the elimination of deuterium labelled carbamazepine in the rat. (1978) (11)
- Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. (2004) (10)
- Plasma Levels of 25‐Hydroxyvitamin D3 and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives (2014) (10)
- Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin (2018) (10)
- Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype (2018) (10)
- Electroconvulsive Therapy Effects on Cerebrospinal Fluid Monoamine Metabolites and Platelet Serotonin Uptake In Melancholia. (1986) (9)
- Comments to "interaction between caffeine and clozapine". (1995) (9)
- Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients (2017) (9)
- Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV) (1999) (9)
- Treatment of depression with E-10-hydroxynortriptyline — a pilot study on biochemical effects and pharmacokinetics (2005) (9)
- Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. (1993) (9)
- Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations (2006) (8)
- Pharmacogenetics of Drug Metabolism: Two Clinically Important Polymorphic Enzymes, CYP2D6 and TPMT (2005) (8)
- An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin. (1997) (8)
- Serotonin and noradrenaline uptake inhibitors in the treatment of depression – relationship to 5‐HIAA in spinal fluid (1981) (8)
- 617 – PHARMACOKINETICS OF INDOMETHACIN IN MAN (1977) (8)
- No Effect on Plasma Carbamazepine Concentration with Concomitant Omeprazole Treatment (1995) (7)
- Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. (2003) (7)
- N-terminally extended substance P is released together with substance P from rat spinal cord (1990) (7)
- Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. (1989) (7)
- Methylation and Racemisation Studies on Usnic Acid. (1968) (7)
- Rapid conjugation in an extremely rapid hydroxylator of debrisoquine: a case report supporting a coregulation of certain phase I and II metabolic reactions. (1988) (7)
- The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans (2012) (6)
- Neuropeptide K is present in human cerebrospinal fluid. (1990) (6)
- Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. (1993) (6)
- Studies on the metabolism and pharamcokinetics of nortriptyline and desmethylimipramine in man. (1971) (5)
- E-10-hydroxynortriptyline: effects and disposition of a potential novel antidepressant. (1989) (5)
- N-terminally extended tachykinins in human cerebrospinal fluid (1992) (5)
- Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites (2004) (5)
- DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE (1989) (5)
- Quantitation of N-terminally extended tachykinins in cerebrospinal fluid from healthy subjects (1994) (4)
- Acute dystonic reactions in Saudi Arabian psychiatric patients treated with haloperidol (1987) (4)
- [Genotyping for drug metabolism capacity can give valuable clinical information]. (1992) (4)
- Monoamine metabolites in cerebrospinal fluid during treatment with clonidine or alprenolol (1977) (4)
- The action of fenfluramine andp-chloramphetamine on serotonergic mechanisms: A comparative study in rat brain nuclei (1976) (4)
- N-terminally extended tachykinins in human cerebrospinal fluid (1988) (4)
- Stereospecific 10-hydroxylation of nortriptyline — genetic aspects and importance for biochemical and clinical effects (1983) (4)
- Kinetics, metabolism and effects of carbamazepine-10,11-epoxide in man. (1991) (3)
- Formation of a Tetracyclic Furan Derivative from Usnic Acid and Diazomethane. (1968) (3)
- Effects of valpromide and viloxazine on the elimination of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. (1989) (3)
- Pharmacogenetic Aspects of Neuroleptic Malignant Syndrome (2006) (3)
- gamma-aminobutyric acid in rat superior cervical ganglion. (1976) (3)
- Studies on active transport of (E)-10-hydroxynortriptyline in the kidney and brain of rats: effects of propranolol and quinidine. (1991) (3)
- P.2.a.028 Monoamine metabolites level in CSF are related to the 5-HTT gene polymorphism in treatment-resistant depression (2007) (2)
- Dose of Proton Pump Inhibitors and the CYP2C19 Genotype (2004) (2)
- TREATMENT WITH DISULFIRAM IN HUNTINGTON'S CHOREA (1974) (2)
- Clinical relevance of the CYP2D6 polymorphism for the treatment of psychiatric disorders (2002) (2)
- Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects (1987) (2)
- The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related disease (1998) (2)
- Carbamazepine in trigeminal neuralgia: clinical effects in relation to plasma-concentration. (1980) (2)
- [Clinical pharmacology of carbamazepine--a comparison with phenytoin]. (1985) (2)
- Monoamine metabolites in cerebrospinal fluid during treatment of hypertension with prazosin (1980) (2)
- GENETIC FACTORS IN THE METABOLISM OF HALOPERIDOL. (1992) (2)
- P.1.034 In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine (1997) (2)
- Active metabolites of antidepressants: novel aspects of hydroxylation and demethylation in man (1981) (1)
- Carbamazepine metabolism in man ‐ Influence of auto and hetero‐induction on some different oxidative pathways (1984) (1)
- Molecular basis of drug oxidation polymorphisms (1993) (1)
- Disposition and Effects of E-10-Hydroxynortriptyline—An Active Metabolite of Nortriptyline (1989) (1)
- Genetic Variability in Man as a Complicating Factor in the Extrapolation of Toxicological Data from Animals (1982) (1)
- Mass fragmentography in clinical psychopharmacology. (1973) (1)
- INTERETHNIC DIFFERENCES IN DRUG OXIDATION. IMPLICATIONS FOR THE UTILIZATION OF ANTIDEPRESSANTS AND NEUROLEPTICS (1992) (1)
- MP666INFLAMMATION DOWN REGULATES CYTOCHROME P450 MEDINATED DRUG METABOLISM IN HEMODIALYSIS PATIENTS (2016) (1)
- Influence of CYP3A4 activity on imatinib response in paitents with chronic myeloid leukemia (2006) (1)
- Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes (1982) (1)
- A comparison of haloperidol plasma levels among Japanese, Korean and Swedish psychiatric patients (2010) (1)
- Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers (2021) (0)
- Symposium Genetic Factors Influencing Drug Action (1983) (0)
- DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY - METHODS AND BIOCHEMICAL STUDIES OF DEPRESSIVE DISORDERS (1976) (0)
- 480 Activity of Cyp3A in Mothers and Their Newborns Using 4B-Hydroxycholesterol as a Marker (2010) (0)
- CLINICAL STUDIES OF CYP 3 A 4 AND P-GLYCOPROTEIN (2016) (0)
- EFFECT OF NIFEDIPINE ON ANALGESIA INDUCED BY GABAa AND GABAB RECEPTOR AGONISTS IN RATS (2013) (0)
- Lower CYP2C9 activity in Turkish patients with Behçet’s disease compared to healthy subjects: a down-regulation due to inflammation? (2015) (0)
- Studies on whether or not diazepam affects the dynamics of amitriptyline. (1987) (0)
- metabolic reaction is important in the disposition of the drug. (1981) (0)
- Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients (2018) (0)
- Interphenotype differences indisposition andeffect on gastrin levels ofomeprazole-suita bility ofomeprazole as aprobe forCYP2C19 (1995) (0)
- The effects of long-term omeprazole therapy on gastrin, pepsinogen I, and chromogranin A concentrations are related to CYP2C19 polymorphism. (2000) (0)
- PHARMACOKINETICS OF CARBAMAZEPINE‐10, 11‐EPOXIDE IN HEALTHY VOLUNTEERS: (1982) (0)
- Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation (2011) (0)
- The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans (2012) (0)
- Cytochrome P 450 enzymes affected by artemisinin antimalarials – pharmacokinetic and pharmacogenetic aspects (2008) (0)
- N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians (2018) (0)
- Rifampicin and CYP2B6 Genotype Influence efavirenz Autoinduction and hence Plasma Exposure (2012) (0)
- Biochemical and clinical effects of amiflamine-determined by the debrisoquine hydroxylation phenotype? (1987) (0)
- Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology (2020) (0)
- Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes (2012) (0)
- Investigating the determinants of efavirenz pharmacokinetics after long term treatment with and without rifampicin among Tanzanian HIV/TB and HIV patients (2014) (0)
- Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients (2014) (0)
- Persistent mood disorders and cytochrome P450 2D6: influence of the CYP2D6 gene duplication on the development of persistence (2003) (0)
- Involvement of CYP 2 D 6 but not CYP 2 C 19 in nicergoline metabolism in humans (1996) (0)
- SIDE-EFFECTS OF CARBAMAZEPINE: DRUG OR METABOLITE? (1985) (0)
- Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin (2018) (0)
- S.25.01 Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment (2013) (0)
- The use of mass fragmentography in studying the neurobiology of GABA [proceedings]. (1977) (0)
- 1081 – EFFECTS OF CHLORIMIPRAMINE ON AMINE METABOLITES IN CEREBROSPINAL FLUID OF DEPRESSED PATIENTS - RELATIONSHIP TO INHIBITION OF SEROTONIN UPTAKE (1977) (0)
- Develoment of pharmacogenomicsduring 40 years―CYP2D6 and CYP2C19 as examples (2019) (0)
- CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo (2006) (0)
- Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype (2018) (0)
- Use of stable isotopes in drug disposition studies in man (1988) (0)
- 1455 – DETERMINATION OF BIOGENIC AMINE METABOLITES IN CEREBROSPINAL FLUID BY MASS FRAGMENTOGRAPHY - METHODS AND 3I0CHEMICAL STUDIES OF DEPRESSIVE DISORDERS (1977) (0)
- [Studies of indolamine metabolites in cerebrospinal fluid in depression]. (1972) (0)
- N-terminally extended tachykinins in human cerebrospinal fluid (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Leif Bertilsson?
Leif Bertilsson is affiliated with the following schools:
